Abstract:Preeclampsia accounts for one of the most common documented gestational complications, with a prevalence of approximately 2 to 15% of all pregnancies. Defined as gestational hypertension after 20 weeks of pregnancy and coexisting proteinuria or generalized edema, and certain forms of organ damage, it is life-threatening for both the mother and the fetus, in terms of increasing the rate of mortality and morbidity. Preeclamptic pregnancies are strongly associated with significantly higher medical costs. The maternal costs are related to the extra utility of the healthcare system, more resources used during hospitalization, and likely more surgical spending due to an elevated rate of cesarean deliveries. The infant costs also contribute to a large percentage of the expenses as the babies are prone to preterm deliveries and relevant or causative adverse events. Preeclampsia imposes a considerable financial burden on our societies. It is important for healthcare providers and policy-makers to recognize this phenomenon and allocate enough economic budgets and medical and social resources accordingly. The true cellular and molecular mechanisms underlying preeclampsia remain largely unexplained, which is assumed to be a two-stage process of impaired uteroplacental perfusion with or without prior defective trophoblast invasion (stage 1), followed by general endothelial dysfunction and vascular inflammation that lead to systemic organ damages (stage 2). Risk factors for preeclampsia including race, advanced maternal age, obesity, nulliparity, multi-fetal pregnancy, and co-existing medical disorders, can serve as warnings or markers that call for enhanced surveillance of maternal and fetal well-being. Doppler ultrasonography and biomarkers including the mean arterial pressure (MAP), uterine artery pulsatility index (UtA-PI), and serum pregnancy-associated plasma protein A (PAPP-A) can be used for the prediction of preeclampsia. For women perceived as high-risk individuals for developing preeclampsia, the administration of low-dose aspirin on a daily basis since early pregnancy has proven to be the most effective way to prevent preeclampsia. For preeclamptic females, relevant information, counseling, and suggestions should be provided to facilitate timely intervention or specialty referral. In pregnancies complicated with preeclampsia, closer monitoring and antepartum surveillance including the Doppler ultrasound blood flow study, biophysical profile, non-stress test, and oxytocin challenge test can be arranged. If the results are unfavorable, early intervention and aggressive therapy should be considered. Affected females should have access to higher levels of obstetric units and neonatal institutes. Before, during, and after delivery, monitoring and preparation should be intensified for affected gravidas to avoid serious complications of preeclampsia. In severe cases, delivery of the fetus and the placenta is the ultimate solution to treat preeclampsia. The current review is a summary of recent advances regarding the knowledge of preeclampsia. However, the detailed etiology, pathophysiology, and effect of preeclampsia seem complicated, and further research to address the primary etiology and pathophysiology underlying the clinical manifestations and outcomes is warranted.

Innate Immunity, Decidual Cells, and Preeclampsia

Pre-Eclampsia: Re-visiting Pathophysiology, Role of immune cells in Pre-Eclampsia, Biomarker identification and recent advances in its Management

The role of immune cells and mediators in preeclampsia

The central role of natural killer cells in preeclampsia

Revisiting preeclampsia: a metabolic disorder of the placenta

The Roles of Uterine Natural Killer (NK) Cells and KIR/HLA-C Combination in the Development of Preeclampsia: A Systematic Review

Mechanisms of Key Innate Immune Cells in Early- and Late-Onset Preeclampsia

A Systematic Review of the Molecular Mechanisms

Changes in expression levels of immune cells and inflammatory cytokines in pre-eclampsia patients before and after delivery

The genetic relationships between immune cell traits, circulating inflammatory proteins and preeclampsia/eclampsia

Placental Imbalance of Th1‐ and Th2‐type Cytokines in Preeclampsia

Elevated Serum Levels of Interleukin-15 and Interleukin-16 in Preeclampsia.

Immune Cells and Infectious Diseases in Preeclampsia Susceptibility

Research Progress on Extracellular Matrix Involved in the Development of Preeclampsia

Phenotypic and Functional Alteration of CD45+ Immune Cells in the Decidua of Preeclampsia Patients Analyzed by Mass Cytometry (Cytof)

Excessive Immune Activation and the Correlation with Decreased Expression of PD-1 at the Maternal–Fetal Interface in Preeclampsia

Preeclampsia: Short- and Long-Term Effects

Progress in the understanding of the pathophysiology of immunologic maladaptation related to early-onset preeclampsia and metabolic syndrome related to late-onset preeclampsia

Preeclampsia and transport of ions and small molecules: A literature review

Dissecting human trophoblast cell transcriptional heterogeneity in preeclampsia using single‐cell RNA sequencing

Preeclampsia: Recent Advances in Predicting, Preventing, and Managing the Maternal and Fetal Life-Threatening Condition